discgenics

DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease

DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc…
DiscGenics and Collaborators Announce Breakthrough in Tissue-Engineered Intervertebral Disc Research

DiscGenics and Collaborators Announce Breakthrough in Tissue-Engineered Intervertebral Disc Research
DiscGenics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to IDCT for Degenerative Disc Disease

DiscGenics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to IDCT for Degenerative Disc Disease
POSITIVE TWO-YEAR CLINICAL DATA ANNOUNCED FOR STUDY OF DISCOGENIC PROGENITOR CELL THERAPY (IDCT) FOR DEGENERATIVE DISC DISEASE

POSITIVE TWO-YEAR CLINICAL DATA ANNOUNCED FOR STUDY OF DISCOGENIC PROGENITOR CELL THERAPY (IDCT) FOR DEGENERATIVE DISC DISEASE
DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease

Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain,…
DiscGenics Honored by Goldman Sachs for Entrepreneurship

BioUtah member Discgenics Chairman and CEO Flagg Flanagan Among 100 Most Intriguing Entrepreneurs at 2021 Builders + Innovators…

Call to Action